Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Norovirus GII.4 capsid protein VP1 is the major structural protein forming the outer shell of human norovirus particles. It assembles into icosahedral capsids with T = 3 or T = 4 symmetry, encapsulating the viral RNA genome. The VP1 protein contains an internal N-terminal arm, a shell (S) domain, and a protruding (P) domain. The P domain includes the hypervariable P2 subdomain, which is critical for host cell attachment via glycan/histoblood group antigen binding and determines antigenicity. Sequence variation in the P2 domain drives immune escape and frequent emergence of epidemic variants. VP1 virus-like particles are used in norovirus vaccine development, making it a major therapeutic and diagnostic target[1][2][3][4].
Drugs and antibodies under investigation bind the VP1 protein to block cell attachment or induce neutralizing immune responses (vaccine mechanism)[1][3]. Vaccine-induced antibodies recognize conformational epitopes on VP1, particularly the hypervariable P2 domain.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Norovirus GII.4 capsid protein VP1 (VP1 (GII.4)).